Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530173 | 1.00 | HRH4 (0.34) | HRH4ATMHTT | |
| SCHEMBL1723557 | 1.00 | HRH4 (0.34) | HRH4ATMHTT | |
| Acetic Acid SCHEMBL3252801 | 0.88 | ATM (0.39) | HRH4ATM | |
| SCHEMBL528916 | 0.86 | ATM (0.31) | ATMHTT | |
| SCHEMBL5256302 | 0.86 | ATM (0.31) | ATMHTT | |
| SCHEMBL1914630 | 0.86 | ATM (0.31) | ATMHTT | |
| SCHEMBL12047384 | 0.84 | ATM (0.40) | ATMHTT | |
| SCHEMBL680686 | 0.84 | HTT (0.34) | ATMHTT | |
| SCHEMBL13937413 | 0.84 | ATM (0.31) | ATM | |
| SCHEMBL4196476 | 0.84 | ATM (0.31) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023287928-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220315568-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | HRH4 2294/4885ATM 1520/4885HTT 4034/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | HRH4 2119/4885ATM 4286/4885HTT 3996/4885 |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | HRH4 2349/4885ATM 1457/4885HTT 4010/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | HRH4 2586/4885ATM 756/4885HTT 2076/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | HRH4 1225/4885ATM 4279/4885HTT 4284/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | HRH4 1914/4885ATM 1593/4885HTT 4686/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | HRH4 3234/4885ATM 189/4885HTT 2807/4885 |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | HRH4 4304/4885ATM 2621/4885HTT 1674/4885 |
| US-20220315568-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | HRH4 4644/4885ATM 355/4885HTT 923/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | HRH4 697/4885ATM 2997/4885HTT 4638/4885 |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ADRB3, FPR3, RTN3 | HRH4 213/4885ATM 4827/4885HTT 4046/4885 |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | HRH4 1557/4885ATM 1887/4885HTT 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.